Increased expression of collagen receptors: α1β 1 and α2β1 integrins on blood eosinophils in bronchial asthma

Clinical and Experimental Allergy

Volumn 36, Issue 9, 2006, Pages 1184-1191

  Bazan Socha, S ^a   Bukiej, A ^a   Pulka, G ^a   Marcinkiewicz, C ^b   Musial, J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Asthma; Disintegrin; Eosinophil; Extracellular matrix; Integrin

Indexed keywords

CD16 ANTIGEN; COLLAGEN RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DISINTEGRIN; FLUTICASONE; GLUCOCORTICOID; METHYLPREDNISOLONE; SNAKE VENOM; THEOPHYLLINE; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2;

ADULT; ARTICLE; ASTHMA; CELL ADHESION; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EFFECTOR CELL; EOSINOPHIL; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG INFILTRATE; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ASTHMA; CELL ADHESION; COLLAGEN TYPE IV; DISINTEGRINS; EOSINOPHILS; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHA1BETA1; INTEGRIN ALPHA2BETA1; MALE; RECEPTORS, COLLAGEN; VIPER VENOMS;

EID: 33748430937     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02540.x     Document Type: Article

References (40)

1. National Heart, Lung, and Blood Institute. Global Strategy for Asthma Management and Prevention. National Institutes of Health, Bethesda, 1995 Global Initiative for Asthma, Publication No. 95-3659, NHLBI/WHO Workshop Report.
2. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005; 365:974-6.
3. Bousquet J, Chanez A, Vignola J, Lacoste F, Michel FB. Eosinophil infiltration in asthma. Am J Respir Crit Care Med 1994; 150:33-8.
4. Bradley BL, Azzawi M, Jacobson M et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88:661-74.
5. Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004; 59:793-805.
6. Flood-Page P, Menzies-Gow A, Phipps S et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-36.
7. Balzar S, Chu HW, Silkoff P et al. Increased TGF-β2 in severe asthma with eosinophilia. J Allergy Clin Immunol 2005; 115:110-7.
8. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-87.
9. Bazan-Socha S, Bukiej A, Marcinkiewicz C, Musial J. Integrins in pulmonary inflammatory diseases. Curr Pharm Des 2005; 11:893-901.
10. Bochner BS. Verdict in the case of therapies versus eosinophils: the jury is still out. J Allergy Clin Immunol 2004; 113:3-9.
11. Eble JA. Collagen-binding integrins as pharmaceutical targets. Curr Pharm Des 2005; 11:867-80.
12. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720-45.
13. Nomura A, Uchida Y, Sakamoto T et al. Increases in collagen I synthesis in asthma: the role of eosinophils and transforming growth-factor-beta. Clin Exp Allergy 2002; 32:860-5.
14. de Fougerolles AR, Sprague AG, Nickerson-Nutter CL et al. Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest 2000; 105:721-9.
15. Krieglstein CF, Cerwinka WH, Sprague AG et al. Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest 2002; 110:1773-82.
16. Fiorucci S, Mencarelli A, Palazzetti B et al. Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity 2002; 17:769-80.
17. Abraham WM, Ahmed A, Serebriakov I et al. A monoclonal antibody to alpha1beta1 blocks antigen-induced airway responses in sheep. Am J Respir Crit Care Med 2004; 169:97-104.
18. Marcinkiewicz C. Functional characteristic of snake venom disintegrins: potential therapeutic implication. Curr Pharm Design 2005; 7:815-29.
19. Hansel TT, De Vries IJM, Iff T et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991; 145:105-10.
20. Bazan-Socha S, Kisiel DG, Young B et al. Structural requirements of MLD-containing disintegrins for functional interaction with alpha 4 beta 1 and alpha 9 beta1 integrins. Biochemistry 2004; 43:1639-47.
21. Marcinkiewicz C, Vijay-Kumar S, McLane MA, Niewiarowski S. Significance of RGD loop and C-terminal domain of echistatin for recognition of alphaIIbbeta3 and alphavbeta3 integrins and expression of ligand-induced binding site. Blood 1997; 90:1565-75.
22. Ben-Horin S. Bank I. The role of very late antigen-1 in immune-mediated inflammation. Clin Immunol 2004; 113:119-29.
23. Marcinkiewicz C, Weinreb PH, Calvete JJ et al. Obtustatin: a potent selective inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res 2003; 63:2020-3.
24. Humbles AA, Lloyd CM, McMillan SJ et al. A critical role for eosinophils in allergic airways remodeling. Science 2004; 305:1726-9.
25. Koo GC, Shah K, Ding GJF et al. A small molecule very late antigen-4 antagonist can inhibit ovoalbumin-induced lung inflammation. Am J Respir Crit Care Med 2003; 167:1400-9.
26. Ramos-Barbón D, Suzuki M, Taha R et al. Effect of α4-integrin blockade on CD41+ cell-driven late airway responses in the rat. Am J Respir Crit Care Med 2001; 163:101-8.
27. Jackson DY. Alpha 4 integrin antagonists. Curr Pharm Des 2002; 8:1229-53.
28. Gauvreau GM, Becker AB, Boulet L-P et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003; 112:331-8.
29. Rubio MA, Sotillos M, Jochems G, Alvarez V, Corbi AL. Monocyte activation: rapid induction of alpha 1/beta 1 (VLA-1) integrin expression by lipopolysaccharide and interferon-gamma. Eur J Immunol 1995; 25:2701-5.
30. Bocchino V, Bertorelli G, D'Ippolito R et al. The increased number of very late activation antigen-4-positive cells correlates with eosinophils and severity of disease in the induced sputum of asthmatic patients. J Allergy Clin Immunol 2000; 105:65-70.
31. Chiba T, Kamada Y, Saito N et al. RANTES and eotaxin enhance CD11b and CD18 expression on eosinophils from allergic patients with eosinophilia in the application of whole blood flow cytometry analysis. Int Arch Allergy Immunol 2005; 137 (Suppl. 1):12-16.
32. Lantero S, Alessandri G, Spallarossa D, Scarso L, Rossi GA. LFA-1 expression by blood eosinophils is increased in atopic asthmatic children and is involved in eosinophil locomotion. Eur Respir J 1998; 12:1094-8.
33. Sklar LA, Tsuji H, Edwards BS, Larson RS, Schuyler M. Eosinophil traffic in the circulation following allergen challenge. Allergy 2004; 59:596-605.
34. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23:290-6.
35. Luijk B, Lindemans CA, Kanters D et al. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. J Allergy Clin Immunol 2005; 115:997-1003.
36. Lim LH, Flower RJ, Perretti M, Das AM. Glucocorticoid receptor activation reduces CD11b and CD49d levels on murine eosinophils: characterization and functional relevance. Am J Respir Cell Mol Biol 2000; 22:693-701.
37. Kisiel DG, Calvete JJ, Katzhendler J, Fertala A, Lazarovici P, Marcinkiewicz C. Structural determinants of the selectivity of KTS-disintegrins for the alpha1beta1 integrin. FEBS Lett 2004; 577:478-82.
38. Paz Moreno-Murciano M, Monleon D, Marcinkiewicz C, Calvete JJ, Celda B. NMR solution structure of the non-RGD disintegrin obtustatin. J Mol Biol 2003; 329:135-45.
39. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353:227-31.
40. Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006; 354:965-7.